Daprodustat: First Approval

<p><b>Declarations</b></p><p><b> Funding</b> The preparation of this review was not supported by any external funding. </p><p><b>Authorship and Conflict of interest</b> S. Dhillon is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conficts of interest. All authors contributed to the review and are responsible for the article content. </p><p><b>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</b> Not applicable.</p><p>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a><b></b></p><p><br></p><p><b>Abstract</b></p><p>Daprodustat (Duvroq) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease (CKD). Inhibition of PHD prevents degradation of hypoxia-inducible factor (HIF), leading to the production of erythropoietin and subsequent induction of erythropoiesis. In June, daprodustat received its first approval in Japan for the treatment of renal anaemia. Clinical studies of daprodustat are underway in multiple countries worldwide. This article summarizes the milestones in the development of daprodustat leading to this first approval for the treatment of renal anaemia.<br></p><p><br></p><p>© Springer Nature Switzerland AG 2020</p>